Skip Navigation


European Heart Journal Advance Access originally published online on February 3, 2009
European Heart Journal 2009 30(4):387-388; doi:10.1093/eurheartj/ehp026
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/4/387    most recent
ehp026v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pitt, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pitt, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

Aldosterone blockade in patients with heart failure and a reduced left ventricular ejection fraction

Bertram Pitt*

Division of Cardiology, University of Michigan School of Medicine, 1500 E Medical Center Drive, 3910 Taubman Center, Ann Arbor, MI 48109-0366, USA

* Corresponding author. Tel: +1 734 936-5260, Fax: +1 734 936-5256, Email: bpitt@umich.edu

This editorial refers to ‘Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials’{dagger}, by J.A. Ezekowitz and F.A. McAlister on page 469

Footnotes

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

The first 10% of the full text of this article appears below.

Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-adrenergic receptor blockers (BBs), and aldosterone blockers (ABs) have been shown to be effective in reducing cardiovascular mortality and the need for hospitalizations for heart failure (HF) in patients with chronic HF and a reduced left ventricular ejection fraction (HFREF) and in patients with HFREF post-myocardial infarction (MI). The use of ACEIs, ARBs, and BBs in appropriate patients in clinical practice has, however, been far greater than for ABs.1 There are probably a number of reasons for this apparent gap in the application of ABs to . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials
Justin A. Ezekowitz and Finlay A. McAlister
EHJ 2009 30: 469-477. [Abstract] [Full Text]